# Measuring the Cost Effectiveness of Pharmacogenomic Testing

Kenneth Levy, Ph.D., MBA Adjunct Associate Professor of Medicine Indiana University School of Medicine

### **Disclosures:**


- · The author has no disclosures related to the content of this presentation.
- The INGENIOUS trial (NCT02297126) is sponsored by an NIH/NHGRI U01-grant (HG007762)

# Learning Objectives

- 1. Identify expense, revenue and cost saving parameters prior to implementing an in-house pharmacogenomic testing program
- 2. Selection of key stake-holders, decision makers and implementation team members
- 3. Formulate and develop critical Electronic Medical Record system requirements to support clinical and cost monitoring

### The "Buy or Rent" Decision

Bringing new diagnostic testing in-house is a strategic decision that must be weighed carefully




Pharmacogenomics Cost Justification Upfront analysis can help mitigate the risk





#### Planning and implementation is Critical Include the right people at the right time







### Cost Effectiveness and Sustainability


#### Keys to a successful program

- Detailed pre-planning (with timelines and management tools)
- · Experienced project manager
- · Alignment with key stakeholder's needs
- Staff training and clinical education
- Full integration (input and output) with the Electronic Medical Records system
- Patient and community education

#### **Project Planning**


#### Understanding current and future processes

- Identifies gaps and risks
- Confirms sources of costs
- Validates workflow
- Builds cross-functional alignment



# Project Planning and Workflow

- Transitions workflow into tasks
- Creates dependency relationships between tasks
- Helps to prevent surprises and keep project on-schedule and on-budget



# Stakeholder Alignment

- Senior Executive leadership (CEO/President, CMO, CFO, Chief Legal Officer and CIO)
- Senior Clinical leadership (clinical divisions, nursing and pharmacy)
- · Pathology services
- Clinical staff
- P&T committee<sup>1</sup>
- · Third party payers
- · Patient advocates (community awareness)

<sup>1</sup>ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System

# Key Drivers by Stakeholder

Senior Executive leadership (CEO/President, CMO, CFO, Chief Legal Officer and CIO)

- Impact on clinical outcomes
- Capital budget
- Headcount requirements
- · Standards of Care and legal liability
- Impact on community relations/Patient advocacy groups
- Added time and work burden for clinical staff
- Health Economics, return on overall investment (reimbursement vs cost)
- Integration into LIS/HIS (time and cost)

# Key Drivers by Stakeholder

Senior Clinical leadership (clinical divisions, nursing and pharmacy)

- Technology adoption (National standards of care)
- Impact on malpractice liability
- Education and training (staff turnover)
- Impact on department headcount
- Clinical relevance for each clinical specialty
- Added time and work burden for clinical staff
- Alignment with current workflow

# Key Drivers by Stakeholder

Clinical Staff (physicians, nurses and clinical pharmacists)

- Clinical validation (Peer-reviewed articles, National Standards)
- Clinical Pharmacy consultation availability
- Liability (to act or not act)
- Education (impact on current clinical decision making)
- Alignment with current workflow
- Test turn-around time
- Test reporting format
- Patient education support

# Key Drivers by Stakeholder

#### Third party payers

- Clinical validation (National Standards)
- CMS/other third-party adoption (CPT MoPath code/tier assignment and reimbursement direction)
- Demonstrated/documented clinical and economic data addressing investment versus cost prevention (short and longterm plus hard and soft costs)

# Key Drivers by Stakeholder

#### Patient advocates

- Alignment community needs
- Impact on patient care
- · Cost (out of pocket) to patients
- Patient/community education programs

### Implementation Team Structure




# Test Selection – Where to Start

- Identify institution's most common adverse events associated with gene mediated drug metabolism (informatics committee)
- Quantify frequency (12 to 24 months) of selected adverse events within your patient population (informatics committee)
- Obtain institutions drug volume (in and outpatient) for selected medications (informatics committee and pharmacy benefit manager)
- Quantify internal costs (at the patient level) associated with each adverse event identified

# **Testing Choices**

#### Key Questions/Decisions:

- Will third party payers reimburse for PGx tests not directly linked to an ICD-9 code (i.e panel testing)?
- Prospective (prevention) vs. reactive (atrisk) testing (short vs. long-term impact)
- Individual tests versus disease or medication oriented PGx panels
- Turnaround time (TAT). What is needed vs required? Cost impact linked to changes in TAT



### And Finally the Money *Profit and Loss Analysis*

Justification for Laboratory	Graphic	c exan	nple	only		
Driven by finance committee	Teds per year Rembursement per test Test total resenue	Year_1	Year.2 3.000 \$200 \$200,000	<u>Year 3</u> 4,500 5300,000	Year 4 0.000 \$200 \$1,200.000	Year 5 7,000 5200 51,400,000
Establish metrics to achieve and measure periodically	Expenses Test cost (variable) Headcourt (fixed) Lab misic (variable) Tech (lupport (fixed)		\$ 150,000 \$ 250,000 \$ 23,400 \$ 50,000	\$ 221,000 \$ 250,000 \$ 25,740 \$ 50,000	\$ 300,000 \$ 250,000 \$ 26,314 \$ 50,000	\$ 350,000 \$ 250,000 \$ 31,545 \$ 50,000
<ul> <li>Cash flow, break-even analysis and Net present Value (NPV)</li> </ul>	Tytel Ced		8 473,400	1 550,740	\$ \$29,314	\$ 601,145
	Gross Prote		\$ 126,800	1 349,260	\$ 571,686	\$ 718,855
Operating Profit (OP) before tax and depreciation	GP % M & D G & A (2%) Total Expense	capital \$ 500,000 \$ (500,000)	\$ 80,000 \$ 60,000		\$ 120,000 \$ 120,000 \$ 120,000 \$ 808,314	\$ 140,000 \$ 140,000 \$ 140,000
	Operating Protit Cum OP OP % NPV \$105,039.74 Refi 22%	\$ (500,000) \$ (500,000) -14.9%	\$ 6,600 \$ (#33,430) 25,3%	8 169,260 8 (324,142) 31,8%	\$ 331,686 \$ 7,545 39,6%	\$ 438,855 \$ 446,401 50,4%
Cumulative Income minimum of 5 years	88 22%					

### Summary

- Adopting in-house pharmacogenomic testing requires clinical and financial strategic commitments
- Project teams require engagement from cross-functional areas within the institution
- EMR integration is critical for reporting and data mining
- Education of clinical staff and patients is required for sustainability